APR 24, 2024 | 5:53 PM PDT | BIOCENTURY | MANAGEMENT TRACKS SMART TO LEAD ACTYM AS CEO BY Plus: Ramanayake joins CureVac and updates from Oruka, Madrigal and AusBiotechhttps://www.biocentury.com/article/652223/smart-to-lead-actym-as-ceo© 2024 BioCentury Inc. All Rights Reserved ..read more

APR 24, 2024 | 5:35 PM PDT | BIOCENTURY | REGULATION FDA’S OJEMDA APPROVAL MARKS DAY ONE’S TRANSITION TO COMMERCIAL COMPANY BY No black box warning and a broad label for the pediatric brain cancer therapyhttps://www.biocentury.com/article/652220/fda-s-ojemda-approval-marks-day-one-s-transition-to-commercial-company© 2024 BioCentury Inc. All Rights Reserved ..read more

APR 24, 2024 | 4:47 PM PDT | BIOCENTURY | PRODUCT DEVELOPMENT NEXT-WAVE RADIOPHARMACEUTICALS: INSIGHTS FROM AACR BY Fusion added to view of ɑ-emitters in lutetium-experienced patients, as Novartis, RayzeBio gave peeks at programs with broad indication potentialhttps://www.biocentury.com/article/652147/next-wave-radiopharmaceuticals-insights-from-aacr© 2024 BioCentury Inc. All Rights Reserved ..read more

APR 24, 2024 | 5:03 AM PDT | BIOCENTURY | DEALS AI-GUIDED ANTIBODY DESIGNER BIGHAT TAPS J&J AS LATEST PARTNER AS INTERNAL PIPELINE ADVANCES BY Still years away from the clinic, the biotech now has four deals with larger pharmas that are informing decisions around its wholly-owned programshttps://www.biocentury.com/article/652193/ai-guided-antibody-designer-bighat-taps-j-j-as-latest-partner-as-internal-pipeline-advances© 2024 BioCentury Inc. All Rights Reserved ..read more

APR 23, 2024 | 6:44 PM PDT | BIOCENTURY | PRODUCT DEVELOPMENT CLINICAL REPORT: SANOFI DATA ADVANCES PAIR OF AUTOIMMUNE DISEASE MECHANISMS BY Plus: Neurocrine hits in Phase II depression study and updates from Cerevel, Sage, Ventus, Lilly and AbbViehttps://www.biocentury.com/article/652204/clinical-report-sanofi-data-advances-pair-of-autoimmune-disease-mechanisms© 2024 BioCentury Inc. All Rights Reserved ..read more

APR 23, 2024 | 5:17 PM PDT | BIOCENTURY | MANAGEMENT TRACKS EVOTEC NAMES CHRISTIAN WOJCZEWSKI CEO BY Plus: Novartis proposes Giovanni Caforio as chair and updates from Congruence, Recludix, Calluna and morehttps://www.biocentury.com/article/652206/evotec-names-christian-wojczewski-ceo© 2024 BioCentury Inc. All Rights Reserved ..read more

APR 23, 2024 | 5:11 PM PDT | BIOCENTURY | MARKET ACCESS FINANCIAL INNOVATION NEEDED TO ADVANCE GENE THERAPY BY Report from ICER and NEWDIGS suggests strategies, reforms to help payers adjust to one-time therapieshttps://www.biocentury.com/article/652207/financial-innovation-needed-to-advance-gene-therapy© 2024 BioCentury Inc. All Rights Reserved ..read more

APR 23, 2024 | 11:04 AM PDT | BIOCENTURY | DEALS INCYTE’S HOPES FOR MAST CELL PROGRAM SPUR $750M ESCIENT TAKEOUT BY Deal gives Incyte clinical molecules for inflammatory, dermatological disordershttps://www.biocentury.com/article/652202/incyte-s-hopes-for-mast-cell-program-spur-750m-escient-takeout© 2024 BioCentury Inc. All Rights Reserved ..read more

APR 22, 2024 | 5:35 PM PDT | BIOCENTURY | MANAGEMENT TRACKS BILL MEURY NAMED CEO OF ANTHOS BY Plus: Fujimoto to lead Takeda-Astellas-Sumitomo’s JV, and updates from Sofinnova Partners, SystImmune, Amarna and Cytonushttps://www.biocentury.com/article/652195/bill-meury-named-ceo-of-anthos© 2024 BioCentury Inc. All Rights Reserved ..read more

APR 22, 2024 | 5:19 PM PDT | BIOCENTURY | DEALS DEALS REPORT: TWO JAPANESE PHARMAS SET UP LOCAL BIOTECH INCUBATOR BY Plus: Takeda licenses immuno-oncology program from Kumquat, and deals for Ipsen-Skyhawk, Boehringer-Ochre and more https://www.biocentury.com/article/652191/deals-report-two-japanese-pharmas-set-up-local-biotech-incubator© 2024 BioCentury Inc. All Rights Reserved ..read more